Top

Published in:

Open Access 01-12-2013 | Review

Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity

Authors: Ebtesam A AL-Suhaimi, Adeeb Shehzad

Published in: European Journal of Medical Research | Issue 1/2013

Abstract

Adipose tissue is still regarded as a principle site for lipid storage and mobilizing tissue with an important role in the control of energy homeostasis. Additionally, adipose tissue-secreted hormones such as leptin, visfatin, resistin, apelin, omentin, sex steroids, and various growth factors are now regarded as a functional part of the endocrine system. These hormones also play an important role in the immune system. Several in vitro and in vivo studies have suggested the complex role of adipocyte-derived hormones in immune system and inflammation. Adipokines mediate beneficial and detrimental effects in immunity and inflammation. Many of these adipocytokines have a physiological role in metabolism. The uncontrolled secretions of several adipocytokines were associated with the stimulation of inflammatory processes leading to metabolic disorders including obesity, atherosclerosis, insulin resistance and type 2 diabetes. Obesity leads to the dysfunction of adipocytes andcorrelated with the imbalance of adipokines levels. In obese and diabetic conditions, leptin deficiency inhibited the Jak/Stat3/PI3K and insulin pathways. In this review, ample evidence exists to support the recognition of the adipocyte’s role in various tissues and pathologies. New integral insights may add dimensions to translate any potential agents into the future clinical armamentarium of chronic endocrine metabolic and inflammatory diseases. Functional balance of both adipocytes and immune cells is important to exert their effects on endocrine metabolic disorders; furthermore, adipose tissue should be renamed not only as a functional part of the endocrine system but also as a new part of the immune system.

Available only for authorised users

Hahn P, Novak M: Development of brown and white adipose tissue. J Lipid Res 1975, 16: 79–91.PubMed

Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89: 2548–2556. 10.1210/jc.2004-0395PubMed

Wiecek A, Kokot F, Chudek J, Adamczak M: The adipose tissue–a novel endocrine organ of interest to the nephrologist. Nephrol Dial Transplant 2002, 17: 191–195.PubMed

Matsuzawa Y: Adiponectin: a key player in obesity related disorders. Curr Pharm Des 2010, 16: 1896–1901. 10.2174/138161210791208893PubMed

Singla P, Bardoloi A, Parkash AA: Metabolic effects of obesity: A review. World J Diabetes 2010, 1: 76–88. 10.4239/wjd.v1.i3.76PubMedCentralPubMed

Genc H, Dogru T, Tapan S, Kara M, Ercin CN, Aslan F, Kantarcioglu M, Karslioglu Y, Sertoglu E, Erbil MK, Bagci S: Circulating vaspin and its relationship with insulin sensitivity, adiponectin, and liver histology in subjects with non-alcoholic steatohepatitis. Scand J Gastroenterol 2011, 46: 1355–1361. 10.3109/00365521.2011.603163PubMed

Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M, Hara Y: Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochem Biophys Res Commun 2011, 408: 339–343. 10.1016/j.bbrc.2011.04.039PubMed

Gualillo O, Gonzalez-Juanatey JR, Lago F: The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med 2007, 17: 275–283. 10.1016/j.tcm.2007.09.005PubMed

Galic S, Oakhill JS, Steinberg GR: Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010, 316: 129–139. 10.1016/j.mce.2009.08.018PubMed

10.

Deepa SS, Dong LQ: APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab 2009, 296: E22–36.PubMedCentralPubMed

11.

Tilg H, Moschen AR: Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006, 6: 772–783. 10.1038/nri1937PubMed

12.

Pandzic Jaksic V: Adipocytokines as mediators of metabolic role of adipose tissue. Acta Med Croatica 2010, 64: 253–262.PubMed

13.

Tilg H, Moschen AR: Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond) 2008, 114: 275–288. 10.1042/CS20070196

14.

Williams KW, Scott MM, Elmquist JK: From observation to experimentation: leptin action in the mediobasal hypothalamus. Am J Clin Nutr 2009, 89: 985S-990S. 10.3945/ajcn.2008.26788DPubMedCentralPubMed

15.

Bluher S, Mantzoros CS: Leptin in humans: lessons from translational research. Am J Clin Nutr 2009, 89: 991S-997S. 10.3945/ajcn.2008.26788EPubMedCentralPubMed

16.

Van Harmelen V, Reynisdottir S, Eriksson P, Thorne A, Hoffstedt J, Lonnqvist F, Arner P: Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes 1998, 47: 913–917. 10.2337/diabetes.47.6.913PubMed

17.

Bado A, Levasseur S, Attoub S, Kermorgant S, Laigneau JP, Bortoluzzi MN, Moizo L, Lehy T, Guerre-Millo M, Le Marchand-Brustel Y, Lewin MJ: The stomach is a source of leptin. Nature 1998, 394: 790–793. 10.1038/29547PubMed

18.

Howard JM, Pidgeon GP, Reynolds JV: Leptin and gastro-intestinal malignancies. Obes Rev 2010, 11: 863–874. 10.1111/j.1467-789X.2010.00718.xPubMed

19.

Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, Flier JS: Role of leptin in the neuroendocrine response to fasting. Nature 1996, 382: 250–252. 10.1038/382250a0PubMed

20.

Flier JS: Clinical review 94: What's in a name? In search of leptin's physiologic role. J Clin Endocrinol Metab 1998, 83: 1407–1413. 10.1210/jc.83.5.1407PubMed

21.

Koerner A, Kratzsch J, Kiess W: Adipocytokines: leptin–the classical, resistin–the controversical, adiponectin–the promising, and more to come. Best Pract Res Clin Endocrinol Metab 2005, 19: 525–546. 10.1016/j.beem.2005.07.008PubMed

22.

Konturek PC, Konturek JW, Czesnikiewicz-Guzik M, Brzozowski T, Sito E, Konturek SJ: Neuro-hormonal control of food intake: basic mechanisms and clinical implications. J Physiol Pharmacol 2005, 56(Suppl 6):5–25.

23.

Hegyi K, Fulop K, Kovacs K, Toth S, Falus A: Leptin-induced signal transduction pathways. Cell Biol Int 2004, 28: 159–169. 10.1016/j.cellbi.2003.12.003PubMed

24.

Uotani S, Bjorbaek C, Tornoe J, Flier JS: Functional properties of leptin receptor isoforms: internalization and degradation of leptin and ligand-induced receptor downregulation. Diabetes 1999, 48: 279–286. 10.2337/diabetes.48.2.279PubMed

25.

Myers MG, Cowley MA, Munzberg H: Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 2008, 70: 537–556. 10.1146/annurev.physiol.70.113006.100707PubMed

26.

Konopleva M, Mikhail A, Estrov Z, Zhao S, Harris D, Sanchez-Williams G, Kornblau SM, Dong J, Kliche KO, Jiang S, Snodgrass HR, Estey EH, Andreeff M: Expression and function of leptin receptor isoforms in myeloid leukemia and myelodysplastic syndromes: proliferative and anti-apoptotic activities. Blood 1999, 93: 1668–1676.PubMed

27.

Tsuchiya T, Shimizu H, Horie T, Mori M: Expression of leptin receptor in lung: leptin as a growth factor. Eur J Pharmacol 1999, 365: 273–279. 10.1016/S0014-2999(98)00884-XPubMed

28.

Artwohl M, Roden M, Holzenbein T, Freudenthaler A, Waldhausl W, Baumgartner-Parzer SM: Modulation by leptin of proliferation and apoptosis in vascular endothelial cells. Int J Obes Relat Metab Disord 2002, 26: 577–580. 10.1038/sj.ijo.0801947PubMed

29.

Koda M, Kanczuga-Koda L, Sulkowska M, Surmacz E, Sulkowski S: Relationships between hypoxia markers and the leptin system, estrogen receptors in human primary and metastatic breast cancer: effects of preoperative chemotherapy. BMC Cancer 2010, 10: 320. 10.1186/1471-2407-10-320PubMedCentralPubMed

30.

Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, Nelson C, Lowman HB, Wright BD, Skelton NJ, Frantz GD, Tumas DB, Peale FV Jr, Shelton DL, Hébert CC: FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 2000, 19: 4046–4055. 10.1093/emboj/19.15.4046PubMedCentralPubMed

31.

Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA: The hormone resistin links obesity to diabetes. Nature 2001, 409: 307–312. 10.1038/35053000PubMed

32.

Rajala MW, Lin Y, Ranalletta M, Yang XM, Qian H, Gingerich R, Barzilai N, Scherer PE: Cell type-specific expression and coregulation of murine resistin and resistin-like molecule-alpha in adipose tissue. Mol Endocrinol 2002, 16: 1920–1930. 10.1210/me.2002-0048PubMed

33.

Chumakov AM, Kubota T, Walter S, Koeffler HP: Identification of murine and human XCP1 genes as C/EBP-epsilon-dependent members of FIZZ/Resistin gene family. Oncogene 2004, 23: 3414–3425. 10.1038/sj.onc.1207126PubMed

34.

Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA: Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003, 300: 472–476. 10.1016/S0006-291X(02)02841-3PubMed

35.

Nohira T, Nagao K, Kameyama K, Nakai H, Fukumine N, Okabe K, Kitano S, Hisatomi H: Identification of an alternative splicing transcript for the resistin gene and distribution of its mRNA in human tissue. Eur J Endocrinol 2004, 151: 151–154. 10.1530/eje.0.1510151PubMed

36.

Lazar MA: Resistin- and Obesity-associated metabolic diseases. Horm Metab Res 2007, 39: 710–716. 10.1055/s-2007-985897PubMed

37.

Kusminski CM, McTernan PG, Kumar S: Role of resistin in obesity, insulin resistance and Type II diabetes. Clin Sci (Lond) 2005, 109: 243–256. 10.1042/CS20050078

38.

Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307: 426–430. 10.1126/science.1097243PubMed

39.

Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, Andris F: Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 2002, 32: 3225–3234. 10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-LPubMed

40.

Ray A: Adipokine leptin in obesity-related pathology of breast cancer. J Biosci 2012, 37: 289–294. 10.1007/s12038-012-9191-9PubMed

41.

Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP: Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996, 84: 491–495. 10.1016/S0092-8674(00)81294-5PubMed

42.

Malik KF, Young WS 3rd: Localization of binding sites in the central nervous system for leptin (OB protein) in normal, obese (ob/ob), and diabetic (db/db) C57BL/6J mice. Endocrinology 1996, 137: 1497–1500. 10.1210/en.137.4.1497PubMed

43.

Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372: 425–432. 10.1038/372425a0PubMed

44.

Frederich RC, Hamann A, Anderson S, Lollmann B, Lowell BB, Flier JS: Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1995, 1: 1311–1314. 10.1038/nm1295-1311PubMed

45.

Segal KR, Landt M, Klein S: Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996, 45: 988–991. 10.2337/diabetes.45.7.988PubMed

46.

Van Heek M, Compton DS, France CF, Tedesco RP, Fawzi AB, Graziano MP, Sybertz EJ, Strader CD, Davis HR Jr: Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 1997, 99: 385–390. 10.1172/JCI119171PubMedCentralPubMed

47.

Kobayashi S, Kabuto T, Doki Y, Yamada T, Miyashiro I, Murata K, Hiratsuka M, Kameyama M, Ohigashi H, Sasaki Y, Ishikawa O, Imaoka S: Synchronous esophageal and renal cell carcinoma. Dis Esophagus 2000, 13: 305–310. 10.1046/j.1442-2050.2000.00125.xPubMed

48.

Tartaglia LA: The leptin receptor. J Biol Chem 1997, 272: 6093–6096.PubMed

49.

Bjorbaek C, Kahn BB: Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res 2004, 59: 305–331. 10.1210/rp.59.1.305PubMed

50.

Sousa M, Bras-Silva C, Leite-Moreira A: The role of leptin in the regulation of energy balance. Acta Med Port 2009, 22: 291–298. PortuguesePubMed

51.

Coppola A, Marfella R, Coppola L, Tagliamonte E, Fontana D, Liguori E, Cirillo T, Cafiero M, Natale S, Astarita C: Effect of weight loss on coronary circulation and adiponectin levels in obese women. Int J Cardiol 2009, 134: 414–416. 10.1016/j.ijcard.2007.12.087PubMed

52.

Bates SH, Stearns WH, Dundon TA, Schubert M, Tso AW, Wang Y, Banks AS, Lavery HJ, Haq AK, Maratos-Flier E, Neel BG, Schwartz MW, Myers MG Jr: STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature 2003, 421: 856–859. 10.1038/nature01388PubMed

53.

Munzberg H, Huo L, Nillni EA, Hollenberg AN, Bjorbaek C: Role of signal transducer and activator of transcription 3 in regulation of hypothalamic proopiomelanocortin gene expression by leptin. Endocrinology 2003, 144: 2121–2131. 10.1210/en.2002-221037PubMed

54.

Mori H, Hanada R, Hanada T, Aki D, Mashima R, Nishinakamura H, Torisu T, Chien KR, Yasukawa H, Yoshimura A: Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat Med 2004, 10: 739–743. 10.1038/nm1071PubMed

55.

Ueki K, Kondo T, Kahn CR: Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 2004, 24: 5434–5446. 10.1128/MCB.24.12.5434-5446.2004PubMedCentralPubMed

56.

Metlakunta AS, Sahu M, Yasukawa H, Dhillon SS, Belsham DD, Yoshimura A, Sahu A: Neuronal suppressor of cytokine signaling-3 deficiency enhances hypothalamic leptin-dependent phosphatidylinositol 3-kinase signaling. Am J Physiol Regul Integr Comp Physiol 2011, 300: R1185–1193. 10.1152/ajpregu.00794.2010PubMedCentralPubMed

57.

Sahu A: Intracellular leptin-signaling pathways in hypothalamic neurons: the emerging role of phosphatidylinositol-3 kinase-phosphodiesterase-3B-cAMP pathway. Neuroendocrinology 2011, 93: 201–210. 10.1159/000326785PubMedCentralPubMed

58.

Chen J: The Src/PI3K/Akt pathway may play a key role in the production of IL-17 in obesity. J Leukoc Biol 2010, 87: 355. author reply 357 10.1189/jlb.1009683PubMed

59.

Montagnani M, Golovchenko I, Kim I, Koh GY, Goalstone ML, Mundhekar AN, Johansen M, Kucik DF, Quon MJ, Draznin B: Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem 2002, 277: 1794–1799. 10.1074/jbc.M103728200PubMed

60.

Suganami E, Takagi H, Ohashi H, Suzuma K, Suzuma I, Oh H, Watanabe D, Ojima T, Suganami T, Fujio Y, Nakao K, Ogawa Y, Yoshimura N: Leptin stimulates ischemia-induced retinal neovascularization: possible role of vascular endothelial growth factor expressed in retinal endothelial cells. Diabetes 2004, 53: 2443–2448. 10.2337/diabetes.53.9.2443PubMed

61.

Hausman GJ, Richardson RL: Adipose tissue angiogenesis. J Anim Sci 2004, 82: 925–934.PubMed

62.

Buettner C, Pocai A, Muse ED, Etgen AM, Myers MG Jr, Rossetti L: Critical role of STAT3 in leptin's metabolic actions. Cell Metab 2006, 4: 49–60. 10.1016/j.cmet.2006.04.014PubMedCentralPubMed

63.

Cohen SE, Kokkotou E, Biddinger SB, Kondo T, Gebhardt R, Kratzsch J, Mantzoros CS, Kahn CR: High circulating leptin receptors with normal leptin sensitivity in liver-specific insulin receptor knock-out (LIRKO) mice. J Biol Chem 2007, 282: 23672–23678. 10.1074/jbc.M704053200PubMed

64.

Mojiminiyi OA, Abdella NA: Associations of resistin with inflammation and insulin resistance in patients with type 2 diabetes mellitus. Scand J Clin Lab Invest 2007, 67: 215–225. 10.1080/00365510601032532PubMed

65.

Oliver P, Pico C, Serra F, Palou A: Resistin expression in different adipose tissue depots during rat development. Mol Cell Biochem 2003, 252: 397–400. 10.1023/A:1025500605884PubMed

66.

Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, Zhu Q, Considine RV: Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003, 88: 5452–5455. 10.1210/jc.2002-021808PubMed

67.

Ort T, Arjona AA, MacDougall JR, Nelson PJ, Rothenberg ME, Wu F, Eisen A, Halvorsen YD: Recombinant human FIZZ3/resistin stimulates lipolysis in cultured human adipocytes, mouse adipose explants, and normal mice. Endocrinology 2005, 146: 2200–2209. 10.1210/en.2004-1421PubMed

68.

Mu H, Ohashi R, Yan S, Chai H, Yang H, Lin P, Yao Q, Chen C: Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res 2006, 70: 146–157. 10.1016/j.cardiores.2006.01.015PubMed

69.

Solinas G, Karin M: JNK1 and IKKbeta: molecular links between obesity and metabolic dysfunction. FASEB J 2010, 24: 2596–2611. 10.1096/fj.09-151340PubMed

70.

Ukkola O: Resistin - a mediator of obesity-associated insulin resistance or an innocent bystander? Eur J Endocrinol 2002, 147: 571–574. 10.1530/eje.0.1470571PubMed

71.

Kochan Z, Karbowska J: Resistine–a new hormone secreted by adipose tissue (adipose tissue in insulin resistance). Przegl Lek 2003, 60: 40–42.PubMed

72.

Morash BA, Willkinson D, Ur E, Wilkinson M: Resistin expression and regulation in mouse pituitary. FEBS Lett 2002, 526: 26–30. 10.1016/S0014-5793(02)03108-3PubMed

73.

Brunetti L, Orlando G, Recinella L, Michelotto B, Ferrante C, Vacca M: Resistin, but not adiponectin, inhibits dopamine and norepinephrine release in the hypothalamus. Eur J Pharmacol 2004, 493: 41–44. 10.1016/j.ejphar.2004.04.020PubMed

74.

Tovar S, Nogueiras R, Tung LY, Castaneda TR, Vazquez MJ, Morris A, Williams LM, Dickson SL, Dieguez C: Central administration of resistin promotes short-term satiety in rats. Eur J Endocrinol 2005, 153: R1–5. 10.1530/eje.1.01999PubMed

75.

Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, Bluher M: Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005, 54: 2911–2916. 10.2337/diabetes.54.10.2911PubMed

76.

Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federspil G, Vettor R: Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006, 91: 3165–3170. 10.1210/jc.2006-0361PubMed

77.

Haider DG, Holzer G, Schaller G, Weghuber D, Widhalm K, Wagner O, Kapiotis S, Wolzt M: The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr 2006, 43: 548–549. 10.1097/01.mpg.0000235749.50820.b3PubMed

78.

Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, Kocelak P, Semik-Grabarczyk E, Holecki M, Dabrowski P, Skorupa A: Serum concentration of visfatin in obese women. Metabolism 2007, 56: 1131–1134. 10.1016/j.metabol.2007.04.007PubMed

79.

Jin H, Jiang B, Tang J, Lu W, Wang W, Zhou L, Shang W, Li F, Ma Q, Yang Y, Chen M: Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res Clin Pract 2008, 79: 412–418. 10.1016/j.diabres.2007.09.019PubMed

80.

Sun C, Zhang F, Ge X, Yan T, Chen X, Shi X, Zhai Q: SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab 2007, 6: 307–319. 10.1016/j.cmet.2007.08.014PubMed

81.

Revollo JR, Korner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, Milbrandt J, Kiess W, Imai S: Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007, 6: 363–375. 10.1016/j.cmet.2007.09.003PubMedCentralPubMed

82.

Mercader J, Granados N, Caimari A, Oliver P, Bonet ML, Palou A: Retinol-binding protein 4 and nicotinamide phosphoribosyltransferase/visfatin in rat obesity models. Horm Metab Res 2008, 40: 467–472. 10.1055/s-2008-1065324PubMed

83.

Kloting N, Kloting I: Visfatin: gene expression in isolated adipocytes and sequence analysis in obese WOKW rats compared with lean control rats. Biochem Biophys Res Commun 2005, 332: 1070–1072. 10.1016/j.bbrc.2005.05.058PubMed

84.

Adya R, Tan BK, Punn A, Chen J, Randeva HS: Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008, 78: 356–365. 10.1093/cvr/cvm111PubMed

85.

Ferrante AW Jr, Thearle M, Liao T, Leibel RL: Effects of leptin deficiency and short-term repletion on hepatic gene expression in genetically obese mice. Diabetes 2001, 50: 2268–2278. 10.2337/diabetes.50.10.2268PubMed

86.

Martin SS, Qasim A, Reilly MP: Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 2008, 52: 1201–1210. 10.1016/j.jacc.2008.05.060PubMedCentralPubMed

87.

Kulkarni RN, Wang ZL, Wang RM, Hurley JD, Smith DM, Ghatei MA, Withers DJ, Gardiner JV, Bailey CJ, Bloom SR: Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice. J Clin Invest 1997, 100: 2729–2736. 10.1172/JCI119818PubMedCentralPubMed

88.

Spiegelman BM, Flier JS: Obesity and the regulation of energy balance. Cell 2001, 104: 531–543. 10.1016/S0092-8674(01)00240-9PubMed

89.

Tucholski K, Otto-Buczkowska E: The role of leptin in the regulation of carbohydrate metabolism. Endokrynol Pol 2011, 62: 258–262.PubMed

90.

Morton GJ: Hypothalamic leptin regulation of energy homeostasis and glucose metabolism. J Physiol 2007, 583(Pt 2):437–443.PubMedCentralPubMed

91.

Hillebrand JJ, Geary N: Do leptin and insulin signal adiposity? Forum Nutr 2010, 63: 111–122.PubMed

92.

Davis JF, Choi DL, Benoit SC: Insulin, leptin and reward. Trends Endocrinol Metab 2010, 21: 68–74. 10.1016/j.tem.2009.08.004PubMedCentralPubMed

93.

Levi J, Huynh FK, Denroche HC, Neumann UH, Glavas MM, Covey SD, Kieffer TJ: Hepatic leptin signalling and subdiaphragmatic vagal efferents are not required for leptin-induced increases of plasma IGF binding protein-2 (IGFBP-2) in ob/ob mice. Diabetologia 2012, 55: 752–762. 10.1007/s00125-011-2426-8PubMed

94.

Schultze SM, Hemmings BA, Niessen M, Tschopp O: PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis. Expert Rev Mol Med 2012, 14: e1.PubMed

95.

Kitamura T, Feng Y, Kitamura YI, Chua SC Jr, Xu AW, Barsh GS, Rossetti L, Accili D: Forkhead protein FoxO1 mediates Agrp-dependent effects of leptin on food intake. Nat Med 2006, 12: 534–540. 10.1038/nm1392PubMed

96.

Kohn AD, Barthel A, Kovacina KS, Boge A, Wallach B, Summers SA, Birnbaum MJ, Scott PH, Lawrence JC Jr, Roth RA: Construction and characterization of a conditionally active version of the serine/threonine kinase Akt. J Biol Chem 1998, 273: 11937–11943. 10.1074/jbc.273.19.11937PubMed

97.

Kohn AD, Summers SA, Birnbaum MJ, Roth RA: Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem 1996, 271: 31372–31378. 10.1074/jbc.271.49.31372PubMed

98.

Huang S, Czech MP: The GLUT4 glucose transporter. Cell Metab 2007, 5: 237–252. 10.1016/j.cmet.2007.03.006PubMed

99.

Wallberg-Henriksson H, Zierath JR: GLUT4: a key player regulating glucose homeostasis? Insights from transgenic and knockout mice (review). Mol Membr Biol 2001, 18: 205–211. 10.1080/09687680110072131PubMed

100.

Leturque A, Brot-Laroche E, Le Gall M, Stolarczyk E, Tobin V: The role of GLUT2 in dietary sugar handling. J Physiol Biochem 2005, 61: 529–537. 10.1007/BF03168378PubMed

101.

Zhao FQ, Keating AF: Functional properties and genomics of glucose transporters. Curr Genomics 2007, 8: 113–128. 10.2174/138920207780368187PubMedCentralPubMed

102.

Benomar Y, Naour N, Aubourg A, Bailleux V, Gertler A, Djiane J, Guerre-Millo M, Taouis M: Insulin and leptin induce Glut4 plasma membrane translocation and glucose uptake in a human neuronal cell line by a phosphatidylinositol 3-kinase- dependent mechanism. Endocrinology 2006, 147: 2550–2556. 10.1210/en.2005-1464PubMed

103.

Sainz N, Rodriguez A, Catalan V, Becerril S, Ramirez B, Lancha A, Burgos-Ramos E, Gomez-Ambrosi J, Fruhbeck G: Leptin reduces the expression and increases the phosphorylation of the negative regulators of GLUT4 traffic TBC1D1 and TBC1D4 in muscle of ob/ob mice. PLoS One 2012, 7: e29389. 10.1371/journal.pone.0029389PubMedCentralPubMed

104.

Bruss MD, Arias EB, Lienhard GE, Cartee GD: Increased phosphorylation of Akt substrate of 160 kDa (AS160) in rat skeletal muscle in response to insulin or contractile activity. Diabetes 2005, 54: 41–50. 10.2337/diabetes.54.1.41PubMed

105.

Lin Y, Sun Z: Current views on type 2 diabetes. J Endocrinol 2010, 204: 1–11. 10.1677/JOE-09-0260PubMedCentralPubMed

106.

Martinez A, Castro A, Dorronsoro I, Alonso M: Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 2002, 22: 373–384. 10.1002/med.10011PubMed

107.

Clodfelder-Miller B, De Sarno P, Zmijewska AA, Song L, Jope RS: Physiological and pathological changes in glucose regulate brain Akt and glycogen synthase kinase-3. J Biol Chem 2005, 280: 39723–39731. 10.1074/jbc.M508824200PubMedCentralPubMed

108.

Nikoulina SE, Ciaraldi TP, Mudaliar S, Mohideen P, Carter L, Henry RR: Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 2000, 49: 263–271. 10.2337/diabetes.49.2.263PubMed

109.

Weston CR, Davis RJ: Signal transduction: signaling specificity- a complex affair. Science 2001, 292: 2439–2440. 10.1126/science.1063279PubMed

110.

Hill JW, Williams KW, Ye C, Luo J, Balthasar N, Coppari R, Cowley MA, Cantley LC, Lowell BB, Elmquist JK: Acute effects of leptin require PI3K signaling in hypothalamic proopiomelanocortin neurons in mice. J Clin Invest 2008, 118: 1796–1805. 10.1172/JCI32964PubMedCentralPubMed

111.

Namkoong C, Kim MS, Jang PG, Han SM, Park HS, Koh EH, Lee WJ, Kim JY, Park IS, Park JY, Lee KU: Enhanced hypothalamic AMP-activated protein kinase activity contributes to hyperphagia in diabetic rats. Diabetes 2005, 54: 63–68. 10.2337/diabetes.54.1.63PubMed

112.

Goren I, Muller E, Pfeilschifter J, Frank S: Severely impaired insulin signaling in chronic wounds of diabetic ob/ob mice: a potential role of tumor necrosis factor-alpha. Am J Pathol 2006, 168: 765–777. 10.2353/ajpath.2006.050293PubMedCentralPubMed

113.

Al-Harithy RN, Al-Ghamdi S: Serum resistin, adiposity and insulin resistance in Saudi women with type 2 diabetes mellitus. Ann Saudi Med 2005, 25: 283–287.PubMed

114.

Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS: Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 2003, 88: 1730–1736. 10.1210/jc.2002-021604PubMed

115.

Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ: Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003, 149: 331–335. 10.1530/eje.0.1490331PubMed

116.

Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM: Resistin gene expression in human adipocytes is not related to insulin resistance. Obes Res 2002, 10: 1–5. 10.1038/oby.2002.1PubMed

117.

McTernan PG, McTernan CL, Chetty R, Jenner K, Fisher FM, Lauer MN, Crocker J, Barnett AH, Kumar S: Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 2002, 87: 2407. 10.1210/jc.87.5.2407PubMed

118.

Smith SR, Bai F, Charbonneau C, Janderova L, Argyropoulos G: A promoter genotype and oxidative stress potentially link resistin to human insulin resistance. Diabetes 2003, 52: 1611–1618. 10.2337/diabetes.52.7.1611PubMed

119.

Walcher D, Hess K, Berger R, Aleksic M, Heinz P, Bach H, Durst R, Hausauer A, Hombach V, Marx N: Resistin: a newly identified chemokine for human CD4-positive lymphocytes. Cardiovasc Res 2010, 85: 167–174. 10.1093/cvr/cvp278PubMed

120.

Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, Wang J, Rajala MW, Pocai A, Scherer PE, Steppan CM, Ahima RS, Obici S, Rossetti L, Lazar MA: Regulation of fasted blood glucose by resistin. Science 2004, 303: 1195–1198. 10.1126/science.1092341PubMed

121.

Steppan CM, Wang J, Whiteman EL, Birnbaum MJ, Lazar MA: Activation of SOCS-3 by resistin. Mol Cell Biol 2005, 25: 1569–1575. 10.1128/MCB.25.4.1569-1575.2005PubMedCentralPubMed

122.

Shi H, Tzameli I, Bjorbaek C, Flier JS: Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J Biol Chem 2004, 279: 34733–34740. 10.1074/jbc.M403886200PubMed

123.

Qi Y, Nie Z, Lee YS, Singhal NS, Scherer PE, Lazar MA, Ahima RS: Loss of resistin improves glucose homeostasis in leptin deficiency. Diabetes 2006, 55: 3083–3090. 10.2337/db05-0615PubMed

124.

Stofkova A: Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity. Endocr Regul 2010, 44: 25–36. 10.4149/endo_2010_01_25PubMed

125.

Makimura H, Mizuno TM, Bergen H, Mobbs CV: Adiponectin is stimulated by adrenalectomy in ob/ob mice and is highly correlated with resistin mRNA. Am J Physiol Endocrinol Metab 2002, 283: E1266–1271.PubMed

126.

Bauer S, Neumeier M, Wanninger J, Walter R, Kopp A, Bala M, Schaffler A, Buechler C: Systemic resistin is increased in type 2 diabetic patients treated with loop diuretics. J Diabetes Complications 2011, 25: 377–381. 10.1016/j.jdiacomp.2011.06.001PubMed

127.

McGee KC, Harte AL, da Silva NF, Al-Daghri N, Creely SJ, Kusminski CM, Tripathi G, Levick PL, Khanolkar M, Evans M, Chittari MV, Patel V, Kumar S, McTernan PG: Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NFkappaB and JNK in human abdominal subcutaneous adipocytes. PLoS One 2011, 6: e20287. 10.1371/journal.pone.0020287PubMedCentralPubMed

128.

Grunfeld C: Leptin and the immunosuppression of malnutrition. J Clin Endocrinol Metab 2002, 87: 3038–3039. 10.1210/jc.87.7.3038PubMed

129.

Bruno A, Conus S, Schmid I, Simon HU: Apoptotic pathways are inhibited by leptin receptor activation in neutrophils. J Immunol 2005, 174: 8090–8096.PubMed

130.

Otero M, Lago R, Gomez R, Dieguez C, Lago F, Gomez-Reino J, Gualillo O: Towards a pro-inflammatory and immunomodulatory emerging role of leptin. Rheumatology (Oxford) 2006, 45: 944–950. 10.1093/rheumatology/kel157

131.

Stofkova A: Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul 2009, 43: 157–168.PubMed

132.

Sanchez-Margalet V, Martin-Romero C, Santos-Alvarez J, Goberna R, Najib S, Gonzalez-Yanes C: Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action. Clin Exp Immunol 2003, 133: 11–19. 10.1046/j.1365-2249.2003.02190.xPubMedCentralPubMed

133.

Haas P, Straub RH, Bedoui S, Nave H: Peripheral but not central leptin treatment increases numbers of circulating NK cells, granulocytes and specific monocyte subpopulations in non-endotoxaemic lean and obese LEW-rats. Regul Pept 2008, 151: 26–34. 10.1016/j.regpep.2008.05.004PubMed

134.

Lo CK, Lam QL, Yang M, Ko KH, Sun L, Ma R, Wang S, Xu H, Tam S, Wu CY, Zheng BJ, Lu L: Leptin signaling protects NK cells from apoptosis during development in mouse bone marrow. Cell Mol Immunol 2009, 6: 353–360. 10.1038/cmi.2009.46PubMedCentralPubMed

135.

Li Z, Lin H, Yang S, Diehl AM: Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system. Gastroenterology 2002, 123: 1304–1310. 10.1053/gast.2002.35997PubMed

136.

Sennello JA, Fayad R, Morris AM, Eckel RH, Asilmaz E, Montez J, Friedman JM, Dinarello CA, Fantuzzi G: Regulation of T cell-mediated hepatic inflammation by adiponectin and leptin. Endocrinology 2005, 146: 2157–2164. 10.1210/en.2004-1572PubMed

137.

Gruen ML, Hao M, Piston DW, Hasty AH: Leptin requires canonical migratory signaling pathways for induction of monocyte and macrophage chemotaxis. Am J Physiol Cell Physiol 2007, 293: C1481–1488. 10.1152/ajpcell.00062.2007PubMed

138.

Napoleone E, Dis A, Amore C, Baccante G, di Febbo C, Porreca E, de Gaetano G, Donati MB, Lorenzet R: Leptin induces tissue factor expression in human peripheral blood mononuclear cells: a possible link between obesity and cardiovascular risk? J Thromb Haemost 2007, 5: 1462–1468. 10.1111/j.1538-7836.2007.02578.xPubMed

139.

Kim SY, Lim JH, Choi SW, Kim M, Kim ST, Kim MS, Cho YS, Chun E, Lee KY: Preferential effects of leptin on CD4 T cells in central and peripheral immune system are critically linked to the expression of leptin receptor. Biochem Biophys Res Commun 2010, 394: 562–568. 10.1016/j.bbrc.2010.03.019PubMed

140.

Martin-Romero C, Santos-Alvarez J, Goberna R, Sanchez-Margalet V: Human leptin enhances activation and proliferation of human circulating T lymphocytes. Cell Immunol 2000, 199: 15–24. 10.1006/cimm.1999.1594PubMed

141.

Lord GM, Matarese G, Howard JK, Bloom SR, Lechler RI: Leptin inhibits the anti-CD3-driven proliferation of peripheral blood T cells but enhances the production of proinflammatory cytokines. J Leukoc Biol 2002, 72: 330–338.PubMed

142.

Caspar-Bauguil S, Cousin B, Bour S, Casteilla L, Penicaud L, Carpene C: Adipose tissue lymphocytes: types and roles. J Physiol Biochem 2009, 65: 423–436. 10.1007/BF03185938PubMed

143.

Leivo-Korpela S, Lehtimaki L, Vuolteenaho K, Nieminen R, Kankaanranta H, Saarelainen S, Moilanen E: Adipokine resistin predicts anti-inflammatory effect of glucocorticoids in asthma. J Inflamm (Lond) 2011, 8: 12. 10.1186/1476-9255-8-12

144.

Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR: Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 2003, 309: 286–290. 10.1016/j.bbrc.2003.07.003PubMed

145.

Beier JI, Guo L, von Montfort C, Kaiser JP, Joshi-Barve S, Arteel GE: New role of resistin in lipopolysaccharide-induced liver damage in mice. J Pharmacol Exp Ther 2008, 325: 801–808. 10.1124/jpet.108.136721PubMedCentralPubMed

146.

Konrad A, Lehrke M, Schachinger V, Seibold F, Stark R, Ochsenkuhn T, Parhofer KG, Goke B, Broedl UC: Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol 2007, 19: 1070–1074. 10.1097/MEG.0b013e3282f16251PubMed

147.

Adrych K, Smoczynski M, Stelmanska E, Korczynska J, Goyke E, Swierczynski J: Serum adiponectin and leptin concentrations in patients with chronic pancreatitis of alcoholic and nonalcoholic origin. Pancreas 2008, 36: 120–124. 10.1097/MPA.0b013e3181561187PubMed

148.

Almehed K, d'Elia HF, Bokarewa M, Carlsten H: Role of resistin as a marker of inflammation in systemic lupus erythematosus. Arthritis Res Ther 2008, 10: R15. 10.1186/ar2366PubMedCentralPubMed

149.

Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I: Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994, 14: 1431–1437.PubMedCentralPubMed

150.

Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H: Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007, 178: 1748–1758.PubMed

151.

Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC: Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004, 113: 1318–1327.PubMedCentralPubMed

152.

Lago F, Dieguez C, Gomez-Reino J, Gualillo O: Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 2007, 3: 716–724. 10.1038/ncprheum0674PubMed

153.

Gomez R, Conde J, Scotece M, Gomez-Reino JJ, Lago F, Gualillo O: What's new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol 2011, 7: 528–536. 10.1038/nrrheum.2011.107PubMed

Title: Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity
Authors: Ebtesam A AL-Suhaimi
Adeeb Shehzad
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: European Journal of Medical Research / Issue 1/2013
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/2047-783X-18-12

At a glance: The STEP trials

Springer Medicine

Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

RETRACTED ARTICLE: Triptolide ameliorates lipopolysaccharide-induced acute lung injury in rats

The effects and mechanism of ginsenoside Rg1 on myocardial remodeling in an animal model of chronic thromboembolic pulmonary hypertension

Lung flooding enables efficient lung sonography and tumour imaging in human ex vivo and porcine in vivo lung cancer model

Is the covering of the resection margin after distal pancreatectomy advantageous?

RETRACTED ARTICLE: Establishing an osteosarcoma associated protein-protein interaction network to explore the pathogenesis of osteosarcoma

RETRACTED ARTICLE: Effects of uric acid on endothelial dysfunction in early chronic kidney disease and its mechanisms